Wells Fargo Upgrades C R Bard Inc to Outperform

Brokerage firm Wells Fargo Upgrades its rating on C R Bard Inc(NYSE:BCR). The shares have been rated Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by Wells Fargo was issued on Sep 16, 2016.

In a different note, Evercore ISI Group said it Initiates Coverage on C R Bard Inc, according to a research note issued on Sep 15, 2016. The shares have been rated ‘Buy’ by the firm. On Jul 27, 2016, Barclays said it Maintains its rating on C R Bard Inc. In the research note, the firm Raises the price-target to $224.00 per share. The shares have been rated ‘Equalweight’ by the firm. On Jul 27, 2016, Citigroup said it Maintains its rating on C R Bard Inc. In the research note, the firm Raises the price-target to $241.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 27, 2016, Jefferies said it Maintains its rating on C R Bard Inc. In the research note, the firm Raises the price-target to $215.00 per share. The shares have been rated ‘Hold’ by the firm. On Jul 27, 2016, JP Morgan said it Maintains its rating on C R Bard Inc. In the research note, the firm Raises the price-target to $214.00 per share. The shares have been rated ‘Neutral’ by the firm. On Jul 8, 2016, Bank of America said it Downgrades its rating on C R Bard Inc. The shares have been rated ‘Neutral’ by the firm.

C R Bard Inc (BCR) made into the market gainers list on Thursdays trading session with the shares advancing 1.24% or 2.84 points. Due to strong positive momentum, the stock ended at $231.35, which is also near the day’s high of $232. The stock began the session at $228.73 and the volume stood at 4,35,705 shares. The 52-week high of the shares is $239.4299 and the 52 week low is $172.21. The company has a current market capitalization of $16,994 M and it has 7,34,54,615 shares in outstanding.

C R Bard Inc(BCR) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $931.50M. Analysts had an estimated revenue of $915.57M. Earnings per share were $2.54. Analysts had estimated an EPS of $2.47.

Several Insider Transactions has been reported to the SEC. On Sep 8, 2016, Samrat S. Khichi (Sr. VP, Gen Counsel & Secy.) sold 9,183 shares at $221.21 per share price.Also, On Sep 8, 2016, John A Deford (Sr. VP Sci Tech and Clin Afrs) sold 7,928 shares at $221.30 per share price.On Jun 1, 2016, Christopher S Holland (Senior Vice President and CFO) sold 3,970 shares at $219.88 per share price, according to the Form-4 filing with the securities and exchange commission.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

C R Bard Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on C R Bard Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.